Latin, English, French, Spanish: |
| |
|
Recommended INN |
Chemical name or description; Molecular formula: Graphic formula |
| |
|
DCI Recommandée |
Nom chimique ou description; Formule brute; Formule développée |
| |
|
DCI Recomendada |
Nombre químico o descripción; Formula empírica; Formula desarrollada |
| |
|
abrineurinum |
|
abrineurin |
N-L-methionylneurotrophic factor (human brain-derived) cyclic (13→80),(58→109),(68→111)-tris(disulfide), dimer |
| |
|
abrineurine |
dimère du (13→80),(58→109),(68→111)-tris(disulfure) cyclique du L-méthionylfacteur neurotrophique cérébral humain |
| |
|
abrineurina |
dímero del (13→80),(58→109),(68→111)-tris(disulfuro) cíclico del factor N-L-metionilneurotrófico (derivado de cerebro humano) |
| |
|
| |
C587H947N177O177S10 (monomer) |
| |
|
| |

|
| |
|
acidum carglumicum |
|
carglumic acid |
N-carbamoyl-L-glutamic acid |
| |
|
acide carglumique |
acide (2S)-2-(carbamoylamino)pentanedioïque |
| |
|
ácido carglúmico |
ácido N-carbamoil-L-glutámico |
| |
|
| |
C6H10N2O5 |
| |
|
| |

|
| |
|
acidum lidadronicum |
|
lidadronic acid |
[1-amino-3-(dimethylamino)propylidene]diphosphonic acid |
| |
|
acide lidadronique |
acide [1-amino-3-(diméthylamino)propylidène]bisphosphonique |
| |
|
ácido lidadrónico |
ácido[1-amino-3-(dimetilamino)propiliden]difosfónico |
| |
|
| |
C5H16N2O6P2 |
| |
|
| |

|
| |
|
agalsidasum alfa |
|
agalsidase alfa |
human alpha-galactosidase isoenzyme A, isolated from human cell line, clone RAG 001, glycoform α |
| |
|
agalsidase alfa |
isoenzyme A de l’alpha-galactosidase humaine (dimère), glycoforme α produit par la lignée humaine RAG 001 |
| |
|
agalsidasa alfa |
isoenzima A de la alfa-galactosidasa humana glicosilada, aislada de cultivos de células humanas RAG 001, glicoforma α |
| |
|
| |
C2029H3080N544O587S27 (subunit protein moiety reduced) |
| |
|
| |

|
| |
|
agalsidasum beta |
|
agalsidase beta |
α-galactosidase (human clone λAG18 isoenzyme A subunit protein moiety reduced), glycoform β |
| |
|
agalsidase bêta |
isoenzyme A de l’alpha-galactosidase humaine (dimère dont la partie protéique est codée par l’ADN de cellules λAG18 humaines) glycoforme β produit par culture de cellules ovariennes de hamster chinois (CHO) |
| |
|
agalsidasa beta |
isoenzima A de la α-galactosidasa, fracción proteica reducida obtenida del clon humano λAG18, glicoforma β |
| |
|
| |
C2029H3080N544O587S27 (subunit protein moiety reduced) |
| |
|
| |

|
| |
|
alefaceptum |
|
alefacept |
1-92-antigen LFA-3 (human) fusion protein with human immunoglobulin G1 (hinge-CH2-CH3γ1-chain), dimer |
| |
|
aléfacept |
dimère de la protéine de fusion entre le 1-92-LFA-3 humain et la région charnière CH2-CH3 de la chaîne γ1 de l’immunoglobuline G1 humaine |
| |
|
alefacept |
dímero de la proteína de fusión entre el 1-92-antígeno LFA-3 humano y la immunoglobulina G1 (cadena γ1 bisagra-CH2-CH3) |
| |
|
| |
C3264H5002N840O988S20 |
| |
|
| |

|
| |
|
alfatradiolum |
|
alfatradiol |
estra-1,3,5(10)-triene-3,17α-diol |
| |
|
alfatradiol |
estra-1,3,5(10)-triène-3,17α-diol |
| |
|
alfatradiol |
estra-1,3,5(10)-trieno-3,17α-diol |
| |
|
| |
C18H24O2 |
| |
|
| |

|
| |
|
aprepitantum |
|
aprepitant |
3-[[(2R,3S)-3-(p-fluorophenyl)-2-[[(αR)-α-methyl- 3,5-bis(trifluoromethyl)benzyl]oxy]morpholino]methyl]-Δ3-1,2,4- triazolin-5-one |
| |
|
aprépitant |
5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluorométhyl)phényl]éthoxy]-3- (4-fluorophényl)morpholin-4-yl]méthyl]-1,2-dihydro-3H-1,2,4- triazol-3-one |
| |
|
aprepitant |
5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluorometil)fenil]etoxi]- 3-(4-fluorofenil)morfolin-4-il]metil]-1,2-dihidro-3H-1,2,4-triazol-3-ona |
| |
|
| |
C23H21F7N4O3 |
| |
|
| |

|
| |
|
atrasentanum |
|
atrasentan |
(2R,3R,4S)-1-[(dibutylcarbamoyl)methyl]-2-(p-methoxyphenyl)- 4-[3,4-(methylenedioxy)phenyl]-3-pyrrolidinecarboxylic acid |
| |
|
atrasentan |
acide (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)- 2-oxoéthyl]-2-(4-méthoxyphényl)pyrrolidine-3-carboxylique |
| |
|
atrasentán |
ácido (2R,3R,4S)-1-[(dibutilcarbamoil)metil]-2-(p-metoxifenil)- 4-[3,4-(metilenodioxi)fenil]-3-pirrolidinacarboxílico |
| |
|
| |
C29H38N2O6 |
| |

|
| |
|
aviscuminum |
|
aviscumine |
toxin ML-I (mistletoe lectin I) (Viscum album) |
| |
|
aviscumine |
toxine ML-I (lectine I de gui) (Viscum album) obtenue par génie génétique, constituée par deux chaînes peptidiques A (250 amino-acides) et B (264 amino-acides) liées entre elles par un pont disulfure |
| |
|
aviscumina |
toxina ML-I (lectina I de muérdago) (Viscum album) obtenida por ingeniaria genética, constituida por dos cadenas peptídicas A (250 aminoácidos) y B (264 aminoácidos) unidas entre si por un puente disulfuro |
| |
|
| |
C1251H1956N346O374S5 (A) C1255H1983N363O394S15 (B) |
| |
|
| |

|
| |
|
balaglitazonum |
|
balaglitazone |
(±)-5-[p-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]benzyl]-2,4-thiazolidinedione |
| |
|
balaglitazone |
(5RS)-5-[4-[(3-méthyl-4-oxo-3,4-dihydroquinazolin-2-yl)méthoxy]benzyl]thiazolidine-2,4-dione |
| |
|
balaglitazona |
(±)-5-[p-[(3,4-dihidro-3-metil-4-oxo-2-quinazolinil)metoxi]bencil]-2,4-tiazolidinadiona |
| |
|
| |
C20H17N3O4S |
| |
|
| |

|
| |
|
bimosiamosum |
|
bimosiamose |
[hexane-1,6-diylbis[6’-(α-D-mannopyranosyloxy)biphenyl- 3’,3-diyl]]diacetic acid |
| |
|
bimosiamose |
acide [hexane-1,6-diylbis[6’-(α-D-mannopyranosyloxy)biphényle- 3’,3-diyl]]diacétique |
| |
|
bimosiamosa |
ácido [hexano-1,6-diylbis[6’-(α-D-manopiranosiloxi)bifenil- 3’,3-diyl]]diacético |
| |
|
| |
C46H54O16 |
| |
|
| |

|
| |
|
brostallicinum |
|
brostallicin |
4-(2-bromoacrylamido)-N’”-(2-guanidinoethyl)-1,1’,1”,1’”-tetramethyl-N,4’:N’,4”:N”,4’”-quater[pyrrole-2-carboxamide] |
| |
|
brostallicine |
4-[[[4-[[[4-[[[4-[(2-bromoprop-2-énoyl)amino]-1-méthyl-1H-pyrrol- 2-yl]carbonyl]amino]-1-méthyl-1H-pyrrol-2-yl]carbonyl]amino]-1- méthyl 1H-pyrrol-2-yl]carbonyl]amino]-N-(2-guanidinoéthyl)-1-méthyl- 1H-pyrrol 2-carboxamide |
| |
|
brostalicina |
4-(2-bromoacrilamido)-N’”-(2-guanidinoetil)-1,1’,1”,1’”-tetrametil N,4’:N’,4”:N”,4’”-cuater[pirrol-2-carboxamida] |
| |
|
| |
C30H35BrN12O5 |
| |
|
| |

|
| |
|
dabigatranum |
|
dabigatran |
N-[[2-[(p-amidinoanilino)methyl]-1-methyl-5-benzimidazolyl]carbonyl]-N-2-pyridyl-β-alanine |
| |
|
dabigatran |
acide 3-[[[2-[[[4-(aminoiminométhyl)phényl]amino]méthyl]-1-méthyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propanoïque |
| |
|
dabigatrán |
N-[[2-[(p-amidinoanilino)metil]-1-metil-5-benzimidazolil]carbonil]-N-2-piridil-β-alanina |
| |
|
| |
C25H25N7O3 |
| |
|
| |

|
| |
|
diflomotecanum |
|
diflomotecan |
(5R)-5-ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy- 3H,15H-oxepino[3’,4’:6,7]indolizino[1,2-b]quinoline-3,15-dione |
| |
|
diflomotécan |
(5R)-5-éthyl-9,10-difluoro-5-hydroxy-1,4,5,13-tétrahydro- 3H,15H-oxépino[3’,4’:6,7]indolizino[1,2-b]quinoléine-3,15-dione |
| |
|
diflomotecán |
(5R)-5-etil-9,10-difluoro-l,4,5,13-tetrahidro-5-hidroxi- 3H,15H-oxepino[3’,4’:6,7]indolizino[1,2-b]quinolina-3,15-diona |
| |
|
| |
C21H16F2N2O4 |
| |
|
| |

|
| |
|
edotreotidum |
|
edotreotide |
N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yI]acetyl] D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2→7)-disulfide |
| |
|
édotréotide |
(2→7)-disulfure cyclique du [N-[[4,7,10-tris(carboxyméthyl)-1,4,7,10tétraazacyclododéc-1-yl]acétyl]-D-phénylalanyl]-L-cystéinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-thréonyl-[N1-[(1R,2R)-2-hydroxy-1-(hydroxyméthyl)propyl]-L-cystéinamide] |
| |
|
edotreotida |
(2→7)-disulfuro cíclico de N-[[4,7,10-tris(carboximetil)-1,4,7,10tetraazaciclododec-1-il]acetil]-D-fenilalanil-L-cisteinil-L-tirosil-D-triptofil-L-lisil-L-treonil-N-[(1R,2R)-2-hidroxi-1-(hidroximetil)propil]-L-cisteinamida |
| |
|
| |
C65H92N14O18S2 |
| |
|
| |

|
| |
|
edronocainum |
|
edronocaine |
N,1-dimethyl-2’-(m-propoxyphenoxy)diethylamine |
| |
|
édronocaïne |
N-méthyl-N-[2-(3-propoxyphénoxy)éthyl]propan-2-amine |
| |
|
edronocaina |
N,1-dimetil-2’-(m-propoxifenoxi)dietilamina |
| |
|
| |
C15H25NO2 |
| |
|
| |

|
| |
|
eflucimibum |
|
eflucimibe |
(S)-2-(dodecylthio)-4’-hydroxy-2’,3’,5’-trimethyl-2-phenylacetanilide |
| |
|
éflucimibe |
(2S)-2-(dodécylsulfanyl)-N-(4-hydroxy-2,3,5-triméthylphényl)- 2-phénylacétamide |
| |
|
eflucimiba |
(S)-2-(dodeciltio)-4’-hidroxi-2’,3’,5’-trimetil-2-fenilacetanilida |
| |
|
| |
C29H43NO2S |
| |
|
| |

|
| |
|
eganoprostum |
|
eganoprost |
methyl (Z)-7-[(1R,2R,3R)-2-[(1E,3S,7R)-3,7-dihydroxy-1-octenyl]-3-hydroxy-5-oxocyclopentyl]-5-heptenoate |
| |
|
éganoprost |
(Z)-7-[(1R,2R,3R)-2-[(1E,3S,7R)-3,7-dihydroxyoct-1-ényl]-3-hydroxy-5-oxocyclopentyl]hept-5-énoate de méthyle |
| |
|
eganoprost |
(Z)-7-[(1R,2R,3R)-2-[(1E,3S,7R)-3,7-dihidroxioct-1-enil]-3-hidroxi-5-oxociclopentil]hept-5-enoato de metilo |
| |
|
| |
C21H34O6 |
| |
|
| |

|
| |
|
emodepsidum |
|
emodepside |
cyclo[(R)-lactoyl-N-methyl-L-leucyl-(R)-3-(p-morpholinophenyl)lactoyl- N-methyl-L-leucyl-(R)-lactoyl-N-methyl-L-leucyl- (R)-3-(p-morpholinophenyl)lactoyl-N-methyl-L-leucyl] |
| |
|
émodepside |
cyclo[(R)-2-hydroxypropanoyl-(N-méthyl-L-leucyl)-[(R)-3-[4-(morpholin-4-yl)phényl]-2-hydroxypropanoyl]-(N-méthyl-L-leucyl)-(R)-2-hydroxypropanoyl-(N-méthyl-L-leucyl)-[(R)-3-[4-(morpholin-4-yl)phényl]-2-hydroxypropanoyl]-(N-méthyl-L-leucyl)] |
| |
|
emodepsida |
ciclo[(R)-lactoil-N-metil-L-leucil-(R)-3-(p-morfolinofenil)lactoil-N-metil-L-leucil-(R)-lactoil-N-metil-L-leucil-(R)-3-(p-morfolinofenil)lactoil-N-metil-L-leucil] |
| |
|
| |
C60H90N6O14 |
| |
|
| |

|
| |
|
erlizumabum |
|
erlizumab |
immunoglobulin G1, anti-(human antigen CD18) (human-mouse monoclonal F(ab’)2 fragment γ1-chain), disulfide with human-mouse monoclonal light chain, dimer |
| |
|
erlizumab |
immunoglobuline G1, anti-(antigène CD18 humain) fragment F(ab’)2 (chaîne γ1 de l’anticorps monoclonal de souris humanisé), dimère du disulfure avec la chaîne légère de l’anticorps monoclonal de souris humanisé |
| |
|
erlizumab |
immunoglobulina G1, anti-(antígeno CD18 humano) fragmento F(ab’)2 (cadena γ1 del anticuerpo monoclonal humanizado de ratón), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de ratón |
| |
|
ertapenemum |
|
ertapenem |
(4R,5S,6S)-3-[[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid |
| |
|
ertapénem |
acide (4R,5S,6S)-3-[[(3S,5S)-5-[(3-carboxyphényl) carbamoyl]pyrrolidin-3-yl]sulfanyl]-6-[(1R)-1-hydroxyéthyl]-4-méthyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ène-2-carboxylique |
| |
|
ertapenem |
ácido (4R,5S,6S)-3-[[(3S,5S)-5-[(3-carboxifenil)carbamoil]pirrolidin-3-il]sulfanil]-6-[(1R)-1-hidroxetil]-4-metil-7-oxo-1-azabiciclo[3.2.0]hept-2-eno-2-carboxilico |
| |
|
| |
C22H25N3O7S |
| |
|
| |

|
| |
|
etoricoxibum |
|
etoricoxib |
5-chloro-6’-methyl-3-[p-(methylsulfonyl)phenyl]-2,3’-bipyridine |
| |
|
étoricoxib |
5-chloro-6’-methyl-3-[4-(méthylsulfonyl)phényl]-2,3’-bipyridyle |
| |
|
etoricoxib |
5-cloro-6’-metil-3-[4-(metilsulfonil)fenil]-2,3’-bipiridilo |
| |
|
| |
C18H15ClN2O2S |
| |
|
| |

|
| |
|
eufauserasum |
|
eufauserase |
broad spectrum serine-protéase enzyme, extracted from the Antartic krill (Euphausia superba) |
| |
|
eufausérase |
protéase à large spectre (enzyme à sérine) extraite de krill de l’Antartique (Euphausia superba) |
| |
|
eufauserasa |
serin-proteasa de amplio espectro extraida del camarón antártico (Euphausia superba) |
| |
|
| |
C1170H1764N300O387S14 |
| |
|
| |

|
| |
|
farglitazarum |
|
farglitazar |
N-(o-benzoylphenyl)-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-L- tyrosine |
| |
|
farglitazar |
acide (2S)-2-[(2-benzoylphényl)amino]-3-[4-[2-(5-méthyl-2- phényloxazol 4-yl)éthoxy]phényl]propanoïque |
| |
|
farglitazar |
ácido (2S)-2-[(2-benzoilfenil)amino]-3-[4-[2-(5-metil-2-feniloxazol- 4-il)etoxi]fenil]propanoico |
| |
|
| |
C34H30N2O5 |
| |
|
| |

|
| |
|
fesoterodinum |
|
fesoterodine |
2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl isobutyrate |
| |
|
fésotérodine |
2-méthylpropanoate de 2-[(1R)-3-[bis(1-méthyléthyl)amino]-1-phénylpropyl]-4-(hydroxyméthyl)phényle |
| |
|
fesoterodina |
2-metilpropanoato de 2-[(1R)-3-[bis(1-metiletil)amino]-1-fenilpropil]-4-(hidroximetil)fenilo |
| |
|
| |
C26H37NO3 |
| |
|
| |

|
| |
|
gavilimomabum |
|
gavilimomab |
immunoglobulin M, anti-(human antigen CD147) (mouse monoclonal ABX-CBL (µ-chain), disulfide with mouse monoclonal ABX-CBL light chain, pentamer |
| |
|
gavilimomab |
immunoglobuline M, anti-(antigène CD147 humain) (chaîne µ de l’anticorps monoclonal de souris ABX-CBL), pentamère du disulfure avec la chaîne légère de l’anticorps monoclonal de souris ABX-CBL |
| |
|
gavilimomab |
immunoglobulina M, anti-(antígeno CD147 humano) (cadena µ del anticuerpo monoclonal de ratón ABX-CBL), pentámero del disulfuro con la cadena ligera del anticuerpo monoclonal de ratón ABX-CBL |
| |
|
gemopatrilatum |
|
gemopatrilat |
(6S)-hexahydro-6-[(αS)-α-mercaptohydrocinnamido]-2,2-dimethyl-7-oxo 1H-azepine-1-acetic acid |
| |
|
gémopatrilate |
acide [(6S)-2,2-diméthyl-7-oxo-6-[[(2S)-3-phényl-2-sulfanylpropanoyl]amino]hexahydro-1H-azépin-1-yl]acétique |
| |
|
gemopatrilat |
ácido [(6S)-2,2-dimetil-7-oxo-6-[[(2S)-3-fenil-2-sulfanilpropanoil]amino]hexahidro-1H-azepin-1-il]acético |
| |
|
| |
C19H26N2O4S |
| |
|
| |

|
| |
|
imatinibum |
|
imatinib |
α-(4-methyl-1-piperazinyl)-3’-[[4-(3-pyridyl)-2-pyrimidinyl]amino]-p-tolu-p-toluidide |
| |
|
imatinib |
4-[(4-méthylpipérazin-1-yl)méthyl]-N-[4-méthyl-3-[[4-(pyridin-3-yl)pirimidin-2-yl]amino]phényl]benzamide |
| |
|
imatinib |
α-(4-metil-1-piperazinil)-3’-[[4-(3-piridil)-2-pirimidinil]amino]-p-tolu-p-toluidida |
| |
|
| |
C29H31N7O |
| |
|
| |

|
| |
|
insulinum glulisinum |
|
insulin glulisine |
[3B-L-lysine,29B-L-glutamic acid]insulin (human) |
| |
|
insuline glulisine |
[3B-L-lysine,29B-L-acide glutamique]insuline humaine |
| |
|
insulina glulisina |
[3B-L-lisina,29B-L-ácido glutámico]insulina humana |
| |
|
| |
C258H384N64O78S6 |
| |
|
| |

|
| |
|
lemalesomabum |
|
lemalesomab |
immunoglobulin G1, anti-(human NCA-90 granulocyte cell antigen) (mouse monoclonal IMMU-MN3 γ1-chain), disulfide with mouse monoclonal IMMU-MN3 κ-chain, dimer |
| |
|
lémalésomab |
immunoglobuline G1, anti-(antigène cellulaire du granulocyte humain NCA-90) (chaîne γ1 de l’anticorps monoclonal de souris IMMU-MN3), dimère du disulfure avec la chaîne κ de l’anticorps monoclonal de souris IMMU-MN3 |
| |
|
lemalesomab |
immunoglobulina G1, anti-(antígeno celular del granulocito humano NCA-90) (cadena γ1 del anticuerpo monoclonal de ratón IMMU-MN3), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón MMU-MN3 |
| |
|
litomeglovirum |
|
litomeglovir |
2-[[4-[[5-(dimethylamino)-1-naphthyl]sulfonamido]phenyl]carbamoyl]-2-methylpropyl glycinate |
| |
|
litoméglovir |
aminoacétate de 3-[[4-[[[5-(diméthylamino)naphtalén-1-yl]sulfonyl]amino]phényl]amino]-2,2-diméthyl-3-oxopropyle |
| |
|
litomeglovir |
aminoacetato de 3-[[4-[[[5-(dimetilamino)naftalen-1-il]sulfonil]amino]fenil]amino]-2,2-dimetil-3-oxopropilo |
| |
|
| |
C25H30N4O5S |
| |
|
| |

|
| |
|
micafunginum |
|
micafungin |
(4R,5R)-4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-(3R)-3-hydroxy-L-glutaminyl-(3S,4S)-3-hydroxy-4-methyl-L-proline cyclic (6→1)-peptide |
| |
|
micafungine |
hydrogénosulfate de 5-[(1S,2S)-2-[(2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-20-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-2,11,12,15 tétrahydroxy-6-[(1R)-1-hydroxyéthyl]-16-méthyl-5,8,14,19,22,25-hexaoxo-9-[[4-[5-[4-(pentyloxy)phényl]isoxazol-3-yl]benzoyl]amino]-tétracosahydro-1H-dipyrrolo[2,1-c:2’,1’-/][1,4,7,10,13,16]hexaazacyclohénicosén-23-yl]1,2-dihydroxyéthyl]-2-hydroxyphényle |
| |
|
micafungina |
hidrógenosulfato de 5-[(1S,2S)-2-[(2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-20-[(1R)-3-amino-1-hidroxi-3-oxopropil]-2,11,12,15-tetrahidroxi-6-[(1R)-1-hidroxietil]-16-metil-5,8,14,19,22,25-hexaoxo-9-[[4-[5-[4(pentiloxi)fenil]isoxazol-3-il]benzoil]amino]-tetracosahidro-1H-dipirrolo[2,1-c:2’,1’-/][1,4,7,10,13,16]hexaazaciclohenicosen-23-il]-1,2-dihidroxietil]-2-hidroxifenilo |
| |
|
| |
C56H71N9O23S |
| |
|
| |

|
| |
|
mozenavirum |
|
mozenavir |
(4R,5S,6S,7R)-1,3-bis(3-aminobenzyl)-4,7-dibenzylhexahydro- 5,6-dihydroxy-2H-1,3-diazepin-2-one |
| |
|
mozénavir |
(4R,5S,6S,7R)-1,3-bis(3-aminobenzyl)-4,7-dibenzyl- 5,6-dihydroxyhexahydro-2H-1,3-diazépin-2-one |
| |
|
mozenavir |
(4R,5S,6S,7R)-1,3-bis(3-aminobencil)-4,7-dibencil-5,6- dihidroxihexahidro-2H-1,3-diazepin-2-ona |
| |
|
| |
C33H36N4O3 |
| |
|
| |

|
| |
|
navuridinum |
|
navuridine |
3’-azido-2’,3’-dideoxyuridine |
| |
|
navuridine |
1-(3-azido-2,3-didésoxy-β-D-érythro-pentofuranosyl)pyrimidine- 2,4(1H,3H)-dione |
| |
|
navuridina |
3’-azido-2’,3’-didesoxiuridina |
| |
|
| |
C9H11N5O4 |
| |
|
| |

|
| |
|
neramexanum |
|
neramexane |
1,3,3,5,5-pentamethylcyclohexylamine |
| |
|
néramexane |
1,3,3,5,5-pentaméthylcyclohexanamine |
| |
|
neramexano |
1,3,3,5,5-pentametilciclohexilamina |
| |
|
| |
C11H23N |
| |
|
| |

|
| |
|
nolomirolum |
|
nolomirole |
(±)-5,6,7,8-tetrahydro-6-(methylamino)-1,2-naphthylene diisobutyrate |
| |
|
nolomirole |
bis(2-méthylpropanoate) de (6RS)-6-(méthylamino)- 5,6,7,8-tétrahydronaphtalène-1,2-diyle |
| |
|
nolomirol |
diisobutirato de (±)-5,6,7,8-tetrahidro-6-(metilamino)-1,2-naftileno |
| |
|
| |
C19H27NO4 |
| |
|
| |

|
| |
|
omaciclovirum |
|
omaciclovir |
9-[(R)-4-hydroxy-2-(hydroxymethyl)butyl]guanine |
| |
|
omaciclovir |
2-amino-9-[(2R)-4-hydroxy-2-(hydroxyméthyl)butyl]-1,9-dihydro- 6H-purin-6-one |
| |
|
omaciclovir |
9-[(R)-4-hidroxi-2-(hidroximetil)butil]guanina |
| |
|
| |
C10H15N5O3 |
| |
|
| |

|
| |
|
omalizumabum |
|
omalizumab |
immunoglobulin G, anti-(human immunoglobulin EFc region) (human-mouse monoclonal E25 clone pSVIE26 γ-chain), disulfide with human-mouse monoclonal E25 clone pSVIE26 κ-chain, dimer |
| |
|
omalizumab |
immunoglobuline G, anti-(région Fc de l’immunoglobuline E humaine) (chaîne γ de l’anticorps monoclonal de souris E25 clone pSVIE26 humanisé), dimère du disulfure avec la chaîne κ de l’anticorps monoclonal de souris E25 clone pSVIE26 humanisé |
| |
|
omalizumab |
immunoglobulina G, anti-(región Fc de la immunoglobulina E humana) (cadena γ del anticuerpo monoclonal humanizado de ratón E25 clon pSVIE26), dímero del disulfuro con la cadena κ del anticuerpo monoclonal humanizado de ratón E25 clon pSVIE26 |
| |
|
peginterferonum alfa-2a |
|
peginterferon alfa-2a |
mono(N2, N6-dicarboxy-L-lysyl)interferon alfa-2a, diesters with polyethylene glycol monomethyl ether The molecular mass of the pegylated part may be indicated in the name by adding a number, for example: peginterferon alfa-2a (40KD). |
| |
|
peginterféron alfa-2a |
interféron alfa-2a dont une des lysines en position 31, 121, 131 ou 134 est acylée par le N2, N6-bis[méthylpoly(oxyéthylène)oxycarbonyl]-L-lysyl La masse molaire de la partie polyéthyléneglycol peut être indiquée dans la DCI, par exemple: peginterféron alfa-2a (40KD). |
| |
|
peginterferón alfa-2a |
diésteres del mono (N2, N6-dicarboxi-L-lisil) interferón α-2a, con polietilenglicolmonometil éter La masa molecular de la parte pegilada, si es necesario, puede indicarse en el nombre añadiendo un número, por ejemplo: peginterferón alfa-2a (40KD). |
| |
|
| |

|
| |
|
peginterferonum alfa-2b |
|
peginterferon alfa-2b |
monocarboxyinterferon alfa-2b, diesters with polyethylene glycol monomethyl ether The molecular mass of the pegylated part may be indicated in the name by adding a number, for example: peginterferon alfa-2b (12KD). |
| |
|
peginterféron alfa-2b |
interféron alfa 2b dont un azote de la cystéine 1 ou d’une lysine 31, 121 ou 134 est engagé dans une liaison carbamate avec l’éther monométhylique du polyéthylène glycol La masse molaire de la partie polyéthyléneglycol peut être indiquée dans la DCI, par exemple: peginterféron alfa-2b (12KD). |
| |
|
peginterferón alfa-2b |
diésteres del monocarboxiinterferón alfa-2b con éter monometílico de polietitenglicol La masa molecular de la parte pegilada, si es necesario, puede indicarse en el nombre añadiendo un número, por ejemplo: peginterferón alfa-2b (12KD). |
| |
|
| |

|
| |
|
pipendoxifenum |
|
pipendoxifene |
2-(p-hydroxyphenyl)-3-methyl-1-[p-(2-piperidinoethoxy)benzyl]indol-5-ol |
| |
|
pipendoxifène |
2-(4-hydroxyphényl)-3-méthyl-1-[4-[2-(pipéridin-1-yl)éthoxy]benzyl]-1H-indol-5-ol |
| |
|
pipendoxifeno |
2-(4-hidroxifenil)-3-metil-1-[4-[2-(piperidin-1-il)etoxi]bencil]-1H-indol-5-ol |
| |
|
| |
C29H32N2O3 |
| |
|
| |

|
| |
|
pitrakinraum |
|
pitrakinra |
L-methionyl-[121-aspartic acid, 124-aspartic acid]interleukin-4 |
| |
|
pitrakinra |
L-méthionyl-[121-acide aspartique, 124-acide aspartique]interleukine-4 |
| |
|
pitrakinra |
L-metionil-[121-ácido aspártico, 124-ácido aspártico]interleucina-4 |
| |
|
| |
C651H1054N190O200S8 |
| |
|
| |

|
| |
|
pradofloxacinum |
|
pradofloxacin |
8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-octahydro-6H pyrrolo[3,4-b)]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
| |
|
pradofloxacine |
acide 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-octahydro-6H pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique |
| |
|
pradofloxacina |
ácido 8-ciano-1-ciclopropil-6-fluoro-7-[(4aS,7aS)-octahidro-6H pirrolo[3,4-b)]piridin-6-il]-4-oxo-1,4-dihidroquinolina-3-carboxilico |
| |
|
| |
C21H21FN4O3 |
| |
|
| |

|
| |
|
reglitazarum |
|
reglitazar |
(4RS)-4-[4-[2-(5-methyl-2-pheny[-4-oxazolyl)ethoxy]benzyl]- 3,5-isoxazolidinedione |
| |
|
réglitazar |
(4RS)-4-[4-[2-(5-méthyl-2-phényloxazol-4-yl)éthoxy]benzyl] isoxazolidine-3,5-dione |
| |
|
reglitazar |
(4RS)-4-[4-[2-(5-metil-2-feniloxazol-4-il)etoxi]bencil]isoxazolidina- 3,5-diona |
| |
|
| |
C22H20N2O5 |
| |
|
| |

|
| |
|
rivoglitazonum |
|
rivoglitazone |
(±)-5-[p-[(6-methoxy-1-methyl-2-benzimidazolyl)methoxy]benzyl]- 2,4-thiazolidinedione |
| |
|
rivoglitazone |
(5RS)-5-[4-[(6-méthoxy-1-méthyl-1H-benzimidazol-2-yl)méthoxy]- benzyl]thiazolidine-2,4-dione |
| |
|
rivoglitazona |
(5RS)-5-[4-[(6-metoxi-1-metil-1H-bencimidazol-2-il)metoxi]bencil] tiazolidina-2,4-diona |
| |
|
| |
C20H19N3O4S |
| |
|
| |

|
| |
|
sabiporidum |
|
sabiporide |
N-carbamimidoyl-4-[4-(1H-pyrrol-2-ylcarbonyl)piperazin-1-yl]- 3-(trifluoromethyl)benzamide |
| |
|
sabiporide |
N-carbamimidoyl-4-[4-(1H-pyrrol-2-ylcarbonyl)pipérazin-1-yl]- 3-(trifluorométhyl)benzamide |
| |
|
sabiporida |
N-carbamimidoil-4-[4-(1H-pirrol-2-ilcarbonil)piperazin-1-il]- 3-(trifluorometil)benzamida |
| |
|
| |
C18H19F3N6O2 |
| |
|
| |

|
| |
|
safinamidum |
|
safinamide |
(+)-(S)-2-[[p-[(m-fluorobenzyl)oxy]benzyl]amino]propionamide |
| |
|
safinamide |
(2S)-2-[[4-(3-fluorobenzyloxy)benzyl]amino]propanamide |
| |
|
safinamida |
(+)-(S)-2-[[p-[(m-fluorobencil)oxi]bencil]amino]propionamida |
| |
|
| |
C17H19FN2O2 |
| |
|
| |

|
| |
|
sibenadetum |
|
sibenadet |
4-hydroxy-7-[2-[[2-[[3-(2-phenylethoxy)propyl]sulfonyl]ethyl]amino]ethyl]benzothiazol-2(3H)-one |
| |
|
sibénadet |
4-hydroxy-7-[2-[[2-[[3-(2-phényléthoxy)propyl]sulfonyl]éthyl]amino]ethyl]benzothiazol-2(3H)-one |
| |
|
sibenadet |
4-hidroxi-7-[2-[[2-[[3-(2-feniletoxi)propil]sulfonil]etil]amino]etil]benzotiazol-2(3H)-ona |
| |
|
| |
C22H28N2O5S2 |
| |
|
| |

|
| |
|
soblidotinum |
|
soblidotin |
N2-(N,N-dimethyl-L-valyl)-N1-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N1-methyl-L-valinamide |
| |
|
soblidotine |
(2S)-2-[[(2S)-2-(diméthylamino)-3-méthylbutanoyl]amino]-N-[(1S,2R)2-méthoxy-4-[(2S)-2-[(1R,2R)-1-méthoxy-2-méthyl-3-oxo-3-[(2-phényléthyl)amino]propyl]pyrrolidin-1-yl]-1-[(1S)-1-méthylpropyl]4-oxobutyl]-N,3-diméthylbutanamide |
| |
|
soblidotina |
(2S)-2-[[(2S)-2-(dimetilamino)-3-metilbutanoil]amino]-N-[(1S,2R)-2-metoxi-4-[(2S)-2-[(1R,2R)-1-metoxi-2-metil-3-oxo-3-[(2-feniletil)amino]propil]pirrolidin-1-il]-1-[(1S)-1-metilpropil]-4-oxobutil]-N,3-dimetilbutanamida |
| |
|
| |
C39H67N5O6 |
| |
|
| |

|
| |
|
soneclosanum |
|
soneclosan |
5-chloro-2-(p-chlorophenoxy)phenol |
| |
|
sonéclosan |
5-chloro-2-(4-chlorophénoxy)phénol |
| |
|
soneclosán |
5-cloro-2-(p-clorofenoxi)fenol |
| |
|
| |
C12H8Cl2O2 |
| |
|
| |

|
| |
|
sumanirolum |
|
sumanirole |
(R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinolin- 2(1H)-one |
| |
|
sumanirole |
(5R)-5-(méthylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoléin- 2(1H)-one |
| |
|
sumanirol |
(5R)-5-(metilamino)-5,6-dihidro-4H-imidazo[4,5,1-ij]quinolin- 2(1H)-ona |
| |
|
| |
C11H13N3O |
| |
|
| |

|
| |
|
taplitumomabum paptoxum |
|
taplitumomab paptox |
immunoglobulin G1, anti-(human antigen CD19) (mouse monoclonal B43 γ1-chain), disulfide with mouse monoclonal B43 κ-chain, dimer, disulfide with protein PAP (pokeweed antiviral) |
| |
|
taplitumomab paptox |
immunoglobuline G1, anti-(antigène humain CD19) (chaîne γ1 de l’anticorps monoclonal de souris B43), dimère du disulfure avec la chaîne κ de l’anticorps monoclonal de souris B43, disulfure avec la protéine antivirale extraite du phytolaque (PAP) |
| |
|
taplitumomab paptox |
immunoglobulina G1, anti-(antígeno humano CD 19) (cadena γ1 del anticuerpo monoclonal de ratón B43), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón B43, disulfuro con la proteína PAP (proteína antiviral de Phytolacca americana) |
| |
|
tezacitabinum |
|
tezacitabine |
2’-deoxy-2’-[(E)-fluoromethylene]cytidine |
| |
|
tézacitabine |
4-amino-1-[(2E)-2-(fluorométylène)-2-désoxy-β-D-érytro pentofuranosyl)pyrimidin-2(1H)-one |
| |
|
tezacitabina |
2’-desoxi-2’-[(E)-fluorometileno]citidina |
| |
|
| |
C10H12FN3O4 |
| |
|
| |

|
| |
|
tidembersatum |
|
tidembersat |
N-[(3R,4S)-6-acetyl-3-hydroxy-2,2-dimethyl-4-chromanyl]-3,5-difluorobenzamide |
| |
|
tidembersat |
N-[(3R,4S)-6-acétyl-3-hydroxy-2,2-diméthyl-3,4-dihydro-2H-1-benzopyran-4-yl]-3,5-difluorobenzamide |
| |
|
tidembersat |
N-[(3R,4S)-6-acetil-3-hidroxi-2,2-dimetil-3,4-dihidro-2H-1-benzopiran-4-il]-3,5-difluorobenzamida |
| |
|
| |
C20H19F2NO4 |
| |
|
| |

|
| |
|
tilmacoxibum |
|
tilmacoxib |
4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluorobenzenesulfonamide |
| |
|
tilmacoxib |
4-(4-cyclohexyl-2-méthyloxazol-5-yl)-2-fluorobenzènesulfonamide |
| |
|
tilmacoxib |
4-(4-ciclohexil-2-metil-5-oxazolil)-2-fluorobencenosulfonamida |
| |
|
| |
C16H19FN2O3S |
| |
|
| |

|
| |
|
tipifarnibum |
|
tipifarnib |
(+)-6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl] 4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone |
| |
|
tipifarnib |
(+)-6-[(R)-amino(4-chlorophényl)(1-méthyl-1H-imidazol-5-yl)méthyl] 4-(3-chlorophényl)-1-méthylquinoléin-2(1H)-one |
| |
|
tipifarnib |
(+)-6-[(R)-amino(4-clorofenil)(1-metil-1H-imidazol-5-il)metil]-4-(3- clorofenil)-1-metilquinolina-2(1H)-ona |
| |
|
| |
C27H22Cl2N4O |
| |
|
| |

|
| |
|
tomeglovirum |
|
tomeglovir |
N-[4-[[[5-(dimethylamino)-1-naphthyl]sulfonyl]amino]phenyl]-3-hydroxy-2,2-dimethylpropionamide |
| |
|
toméglovir |
N-[4-[[[5-(diméthylamino)naphtalén-1-yl]sulfonyl]amino]phényl]-3-hydroxy-2,2-diméthylpropanamide |
| |
|
tomeglovir |
N-[4-[[[5-(dimetilamino)naftalen-1-il]sulfonil]amino]fenil]-3-hidroxi-2,2-dimetilpropanarnida |
| |
|
| |
C23H27N3O4S |
| |
|
| |

|
| |
|
traxoprodilum |
|
traxoprodil |
1-[(1S,2S)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]-4- phenylpiperidin-4-ol |
| |
|
traxoprodil |
1-[(1S,2S)-2-hydroxy-2-(4-hydroxyphényl)-1-méthyléthyl]-4- phénylpipéridin-4-ol |
| |
|
traxoprodil |
1-[(1S,2S)-2-hidroxi-2-(4-hidroxifeni])-1-metiletiI]-4-fenilpiperidin-4-ol |
| |
|
| |
C20H25NO3 |
| |
|
| |

|
| |
|
tridolgosirum |
|
tridolgosir |
(1S,2R,8R,8aR)-octahydro-1,2,8-indolizinetriol |
| |
|
tridolgosir |
(1S,2R,8R,8aR)-octahydroindolizine-1,2,8-triol |
| |
|
tridolgosir |
(1S,2R,8R,8aR)-octahidroindolizina-1,2,8-triol |
| |
|
| |
C8H15NO3 |
| |
|
| |

|
| |
|
valomaciclovirum |
|
valomaciclovir |
L-valine, 4-ester with 9-[(R)-4-hydroxy-2-(hydroxymethyl)butyl]guanine |
| |
|
valomaciclovir |
(2S)-2-amino-3-méthylbutanoate de (3R)-3-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)méthyl]-4-hydroxybutyle |
| |
|
valomaciclovir |
éster de L-valina con (3R)-3-[(2-amino-1,6-dihidro-6-oxo-9H-purin-9-il)metil]-4-hidroxibutilo |
| |
|
| |
C15H24N6O4 |
| |
|
| |

|
| |
|
vatalanibum |
|
vatalanib |
1-(p-chloroanilino)-4-(4-pyridylmethyl)phthalazine |
| |
|
vatalanib |
N-(4-chlorophényl)-4-(pyridin-4-ylméthyl)phtalazin-1-amine |
| |
|
vatalanib |
1-(p-cloroanilino)-4-(4-piridilmetil)ftalazina |
| |
|
| |
C20H15ClN4 |
| |
|
| |

|
| |
|
visilizumabum |
|
visilizumab |
immunoglobulin G2, anti-(human antigen CD3) (human-mouse monoclonal HuM291 γ2-chain), disulfide with human-mouse monoclonal HuM291 κ-chain, dimer |
| |
|
visilizumab |
immunoglobuline G2, anti-(antigène 003 humain) (chaîne γ2 de l’anticorps monoclonal de souris HuM291 humanisé), dimère du disulfure avec la chaîne κ de l’anticorps monoclonal de souris HuM291 humanisé |
| |
|
visilizumab |
immunoglobulina G2, anti-(antígeno CD3 humano) (cadena γ2 del anticuerpo monoclonal humanizado de ratón HuM291), dímero del disulfuro con la cadena κ del anticuerpo monoclonal humanizado de ratón HuM291 |
| |
|
ximelagatranum |
|
ximelagatran |
ethyl N-[(R)-cyclohexyl[[(2S)-2-[[4-(hydroxycarbamimidoyl) benzyl]carbamoyl]-1-azetidinyl]carbonyl]methyl]glycinate |
| |
|
ximélagatran |
[[(1R)-2-[(2S)-2-[[4-[amino(hydroxyimino)méthyl]benzyl] carbamoyl]azétidin-1-yl]-1-cyclohexyl-2-oxoéthyl]amino]acétate d’éthyle |
| |
|
ximelagatrán |
[[(1R)-2-[(2S)-2-[[4-[amino(hidroxiimino)metil]bencil] carbamoil]azetidin-1-il]-1-ciclohexil-2-oxoetil]amino]acetato de etilo |
| |
|
| |
C24H35N5O5 |
| |
|
| |

|
| |
|
zelandopamum |
|
zelandopam |
(-)-(S)-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydro-7,8-isoquinolinediol |
| |
|
zélandopam |
(-)-(4S)-4-(3,4-dihydroxyphényl)-1,2,3,4-tétrahydroisoquinoléine-7,8-diol |
| |
|
zelandopam |
(-)-(S)-4-(3,4-dihidroxifenil)-1,2,3,4-tetrahydro-7,8-isoquinolinediol |
| |
|
| |
C15H15NO4 |
| |
|
| |

|
| |
|
ziralimumabum |
|
ziralimumab |
immunoglobulin M, anti-(human antigen CD147) (human monoclonal ABX-RB2 µ-chain), disulfide with human monoclonal ABX-RB2 light chain, pentamer |
| |
|
ziralimumab |
immunoglobuline M, anti-(antigène CD147 humain) (chaîne µ de l’anticorps monoclonal humain ABX-RB2), pentamère du disulfure avec la chaîne légère de l’anticorps monoclonal humain ABX-RB2 |
| |
|
ziralimumab |
immunoglobulina M, anti-(antígeno CD147 humano) (cadena µ del anticuerpo monoclonal humano ABX-RB2), pentámero del disulfuro con la cadena ligera del anticuerpo monoclonal humano ABX-RB2 |